- Home
- JRS vs BNR Comparison
JRS vs BNR Comparison
Compare JRS & BNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | JRS | BNR |
|---|---|---|
| Founded | 2001 | 2014 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 210.6M | 169.9M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | JRS | BNR |
|---|---|---|
| Price | $7.35 | $12.53 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 72.7K | 28.2K |
| Earning Date | 01-01-0001 | 11-19-2026 |
| Dividend Yield | ★ 8.87% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $101.46 |
| Revenue Next Year | N/A | $14.81 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.12 | $6.79 |
| 52 Week High | $8.90 | $41.72 |
Technical Indicators
Market Signals| Indicator | JRS | BNR |
|---|---|---|
| Relative Strength Index (RSI) | 35.20 | 38.66 |
| Support Level | $7.12 | $8.91 |
| Resistance Level | $7.49 | $12.89 |
| Average True Range (ATR) | 0.12 | 1.50 |
| MACD | 0.03 | -0.63 |
| Stochastic Oscillator | 16.64 | 7.29 |
Price Performance
Historical ComparisonAbout JRS Nuveen Real Estate Income Fund of Beneficial Interest
Nuveen Real Estate Income Fund is a diversified closed-end investment company. The Fund s investment objective is to provide total return through high current income and capital appreciation.
About BNR Burning Rock Biotech Limited
Burning Rock Biotech Ltd is a cancer diagnostics company. The Group provides pharma research and development services, mainly cancer therapy selection tests services, companion diagnostics development services, and other service agreements with the combination of various customized tests services and analytical validation services, to pharmaceutical companies for developing new drugs for targeted therapies, immunotherapies on various types of cancers, and to hospitals for their studies on cancer diagnosis & treatment. It had three operating segments, including the Central laboratory business, the In-hospital business, & Pharma research & development services. It generates the majority of its revenue from the Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, & others.